Your session is about to expire
← Back to Search
Brentuximab + AVD Chemotherapy for Hodgkin's Lymphoma
Study Summary
This trial is testing 4 different Hodgkin Lymphoma treatments to see which is most effective while also limiting long-term side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am 18 years old or older.I have a lymph node mass larger than 7.0 cm.My heart's pumping ability is reduced.My nerve damage does not severely affect my daily activities.My total bilirubin level is 2.0 mg/dl or higher, and I don't have Gilbert's disease.My kidney function, measured by creatinine clearance, is less than 30 mL/min.I have a health condition that my doctor thinks makes joining this study not suitable for me.My cancer is in the early stages (Stage I or II).I am on long-term steroids but can stop for treatment.My Hodgkin lymphoma is CD30 positive.My cancer shows up on PET scans and has a tumor at least 1.5 cm big.
- Group 1: Cohort 1 (completed accrual)
- Group 2: Cohort 2
- Group 3: Cohort 3
- Group 4: Cohort 4
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there room for more participants in this research endeavor?
"The records on clinicaltrials.gov suggest that this study, which was first published on the 1st of May 2013, is not presently seeking participants. However, there are currently 2155 other trials actively recruiting patients."
Have further investigations been carried out regarding Involved-Site Radiation Therapy (ISRT)?
"ISRT was first developed at Spectrum Health Hospital-Butterworth Campus in 1997 and has since seen 795 total clinical trials. Currently, 422 studies are ongoing with many of them based out of Harrison, NY."
In what locations can patients access this research opportunity?
"Currently, 10 trial sites in Harrison, Uniondale, Commack and other nearby cities are enrolling patients for this clinical study. To reduce the burden of travel if you decide to join the research project, select a location close by."
What is the highest capacity of participants for this clinical experiment?
"Currently, no new recruits are being sought for this clinical trial. Initially posted on May 1st 2013 and last updated June 1st 2022, the study is not presently open to applicants. If you seek alternative studies, 1733 trials concerning lymphoma and Hodgkins are actively enrolling participants along with 422 Involved-Site Radiation Therapy (ISRT) clinicals admitting patients right now."
What maladies are commonly treated by Involved-Site Radiation Therapy (ISRT)?
"ISRT is a type of radiation therapy most commonly utilized to combat bladder cancer. It can also be employed for treating Kaposi's Sarcoma, Neoplasm Metastasis or Advanced Thymoma in certain cases."
Is this an unprecedented research endeavor?
"Alfacell's pioneering 1997 study of Involved-Site Radiation Therapy (ISRT) – involving 300 participants – was the first to be completed, eventually earning Phase 3 drug approval. As of today, 422 clinical trials are underway for ISRT in 66 nations and 2053 cities worldwide."
Share this study with friends
Copy Link
Messenger